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these 15 (60%) had achieved counts of> 20/ul on Day -1 itself
[median count of 45.3/ul (range: 21.4e130.2)]. None of the
patients had toxicity related to meloxicam. Subsequently 21
patients underwent auto SCT and their data was compared
with 50 age and disease matched controls who had
mobilization and auto SCT at our center between January
2013 and March 2014. Though mobilization rates and cell
doses were not signiﬁcantly different, the use of meloxicam
and G-CSF was associated with faster neutrophil engraft-
ment. Following auto SCT, there was lower Grade IIIeIV
toxicity, lower transfusion requirement of red cells and
reduction in the duration of hospital stay post SCT [Table 1].
Conclusion: The addition of meloxicam to G-CSF improves
stem cell mobilization and is associated with faster engraft-
ment, no additional toxicity, lower supportive care and lower
duration of hospitalization. It is also potentially possible that
we may be able to harvest the patients a day earlier
depending upon the peripheral blood CD 34 counts achieved.
This datawarrants a prospective randomized trial comparing
Meloxicam + G-CSF with G-CSF alone as a mobilization
strategy prior to autologous stem cell transplantation.Table 1
Vascath (15) CVL (12) p-value
Diagnosis
Neuroblastoma/
Ganglioneuroblastoma
8 7
CNS tumor 3 4
Retinoblastoma 1 0
Lymphoma 2 1
Ewing’s Sarcoma 1 0
Mean # pheresis days 1.2 (1-3) 1.3 (1-2) 0.62
Median weight (kg) 22 (10-120.9) 15.4 (7.45-45.6) 0.06
Median peripheral
blood absolute CD34
count day 1
206 (35.6-766) 354 (12.8-928) 0.5
Median CD34/kg
collected (X 106)
21.5 (6.5-111) 46.7 (13.3-101) 0.06
Median time from admit
to pheresis start
(minutes)
333 (190-607) 179 (80-453) 0.0002
Median total time on
machine (minutes)
245 (121-851) 281 (180-582) 0.3
Mean inlet ﬂow rate
(ml/min)
70.1 (15.9-128.5) 25.5 (9.8-54) 0.002
Mean inlet ﬂow rate/kg 1.56 (0.7-3.95) 2.22 (1.18-2.06) 0.03
Mean # pressure/ﬂow
error readings
0.6 (0-6) 2.4 (0-5) 0.01153
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Background: Early (<12 months from diagnosis) autologous
stem cell transplantation (ASCT) remains a standard treat-
ment for eligible patients with multiple myeloma (MM).
However studies suggest comparable overall survival (OS)
outcomes in patients undergoing delayed (>12 months from
diagnosis) ASCT. Little is known about the outcomes upon
relapse from a delayed ASCT and hence we describe the
natural course of the disease and identify factors that predict
post-ASCT relapse survival in this group of patients.
Patients and Methods: We examined the outcomes of 207
MM patients who underwent a delayed ASCT (12 or more
months from their initial diagnosis) at the Mayo Clinic,
Rochester and then relapsed between 2000 and 2012. Pa-
tients who received a tandem or an allogeneic stem cell
transplant post ﬁrst ASCT were not included in this study.
Multivariate analysis was performed using a Cox propor-
tional hazards model.
Results: Median (range) age at ASCT and at relapse was 62
yrs (40-75) and 63 yrs (40-76) respectively. The median time
to ASCT from MM diagnosis was 30 mos (12-202) and the
median time to relapse post-ASCT was 11 mos (2-100). The
median follow-up (95% CI) from relapse was 78 mos (60-99).
The median (range) number of regimens prior to ASCT was 2
(1-6). Of the 112 patients who had FISH testing at diagnosis,
30% were categorized as high risk. The median (95% CI) LDH
and plasma cell labeling index at diagnosis was 169
(178e215) and 0.6 (1e1.5) respectively. The median (95% CI)
post-ASCT relapse survival (PRS) and overall survival from
diagnosis was 30 (22-36) and 77 (69-87) mos, respectively.
The distribution (N, %) of the post-relapse treatment regi-
mens were as follows: immunomodulator-based (103, 50%),
proteasome inhibitor-based (47, 23%), non-novel agent
chemotherapy (31, 15%), novel investigational therapy (22,
11%) and repeat ASCT (4, 1%). In a multivariate analysis, only
shorter time to relapse, presence of CRAB symptoms orextramedullary disease at relapse, higher pre-ASCT plasma
cell labeling index and LDH predicted for a shorter PRS. The
presence of high-risk cytogenetics by FISH, and choice of
salvage therapy upon relapse post-ASCT did not affect PRS in
the multivariable model.
Conclusion: MM patients who undergo a delayed ﬁrst ASCT
experience improved PRS if they have a longer duration of
response to ASCT, lack CRAB symptoms or extramedullary
disease at relapse (only biochemical progression) and have a
lower pre-ASCT plasma cell labeling index and serum LDH.
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Background and Methods: Large bore venous catheters
such as Vas-cath or hemodialysis catheters are recom-
mended for stem cell pheresis but rarely placed for routine
chemotherapy requiring placement of a second line for
pheresis. Timing pheresis with count recovery and stem cell
collection can be logistically challenging. Due to these chal-
lenges and desire to avoid additional line placement and
anesthesia, we attempted to use double lumen central
venous lines (CVL) for stem cell pheresis in patients who had
them at the time of referral.
Results: Twenty-seven patients underwent stem cell phe-
resis for autologous stem cell transplant from January 2012
to October 2014 utilizing a Cobe Spectra. Patient character-
istics and results (as means/medians and ranges) are detailed
in Table 1. Double lumen CVL was used preferentially for
stem cell pheresis if there was one placed at diagnosis for
chemotherapy and present at time of referral. Thirteen
patients referred for stem cell pheresis had double lumen
CVL (usually 7-9 Fr double lumen Broviacs). The remaining
fourteen patients had either no central line or had
